Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Signing the informed consent form and full understanding study contents, process and possible adverse reactions before participation in the study;~* Able to complete the study according to the requirements of the study protocol;~* The subject (including the partner) is willing to take effective contraceptive measures voluntarily without pregnancy plan in the next 6 months;~* Male and female subjects aged 18 to 65 years (inclusive);~* Male subjects' body weight ≥ 50 kg, or female subjects' body weight ≥ 45 kg, with body mass index within the range of 18-30 kg/m2 (inclusive);~* Health condition: no clinically significant history of heart, liver, kidney, digestive tract, nervous system, respiratory system diseases, mental disorders or metabolic abnormalities;~* Normal results or clinically insignificant abnormal results in physical examinations and vital signs;~* Positive result of 14C urea breath test (UBT).~* Clinical laboratory test results are within normal limits or abnormal but without clinical significance as judged by the investigator.~Exclusion Criteria:~* History of Helicobacter Pyloreradication therapy (including participation in other clinical studies of Helicobacter Pylori eradication);~* Average daily consumption of more than 5 cigarettes within 3 months prior to the start of the study;~* History of hypersensitivity to study drug or its excipients, or allergic constitution (allergy to multiple drugs and food);~* History of drug and/or alcohol abuse (mean consumption of ≥ 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of liquor, or 100 mL of wine);~* Blood donation or massive blood loss (\> 450 mL) within 3 months prior to screening;~* Using any drug that changes liver enzyme activity within 28 days prior to screening;~* Taking orally any prescription drug, over-the-counter drug, any vitamin product, or herbal medicine within 14 days prior to screening;~* Taking special diet (including dragon fruit, mango, grapefruit, etc.) or strenuous exercise, or having other factors that affect drug absorption, distribution, metabolism, excretion, etc., within 2 weeks prior to screening;~* Significant changes in diet or exercise habits recently;~* Those who have participated in, or are still participating in clinical studies within 1 months before taking the study drug t;~* With difficulty in swallowing or history of any gastrointestinal diseases that affect drug absorption;~* With any disease that increases the risk of bleeding, such as hemorrhoids, acute gastritis or gastric and duodenal ulcers;~* With clinically significant ECG abnormalities;~* Female subjects who are lactating during the screening period or during the study, or have positive serum pregnancy test results;~* With symptoms or previous history of cardiovascular, digestive, respiratory, urinary, neurological, hematologic, immunological, endocrine system diseases or tumor, or psychiatric diseases;~* Clinically significant abnormalities in clinical laboratory tests, or other clinically significant findings (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, neoplastic, pulmonary, immunological, psychiatric, or cardiovascular disease);~* Those who have positive tests results of viral hepatitis (including hepatitis B and C), HIV antibody, treponema pallidum antibody (additional RPR test is required for those with positive treponema pallidum antibody);~* Acute illness occurs or concomitant medication is used from the date of signing the informed consent to the date prior to study medication;~* Consumption of chocolate, any caffeine- or xanthine-containing food or drink within 48 hours prior to taking the study drug;~* Consumption of any alcoholic product within 48 hours prior to taking the study drug;~* Those who have positive test result of urine drug screening or history of drug abuse or drug addiction within the past 5 years;~* Those who have other conditions that, in the opinion of the investigator, make participation in this study inappropriate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): TNP2198 capsules 200 mg BID + rabeprazole sodium enteric-coated tablets 20 mg BID
- Group B (Type: EXPERIMENTAL): TNP2198 capsules 400 mg BID + rabeprazole sodium enteric-coated tablets 20 mg BID
- Group C (Type: EXPERIMENTAL): TNP2198 capsules 600 mg BID + rabeprazole sodium enteric-coated tablets 20 mg BID
- Group D (Type: EXPERIMENTAL): TNP2198 capsules 400 mg BID + rabeprazole sodium enteric-coated tablets 20 mg BID + amoxicillin capsules 1g BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete